docetaxel,enzalutamide
pfizer,astellas
['crpc', 'cspc', 'chaarted']
enzada: ph 2 single arm trial of triplet adt/doce/enza for mcspc(n=40) high vol: 75%, de novo: 80%, median psa: 130 1-yr psa cr: 61% (28% w/ adt+doce in chaarted) crpc at 2/4 yrs: 38/47% os at 2/4 yrs: 83/63% no racial diff in outcomes gr 3+ aes: 43% #asco23 
MD, MSc | @UofTUrology @SUO_YUO Fellow & @IHPMEUofT CEHCR PhD| Previously: @MCG_Urology and @AUB_Lebanon 🇱🇧